# OnCo record nct05485948 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05485948/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05485948", "NCT05485948" ;
  schema:name "A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU"@en ;
  schema:description "A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05485948/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05485948> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-10-08" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/polycythaemia-vera/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ropeginterferon-alfa-2b/> ;
  onco:companies <https://onco.cc/companies/pharmaessentia/> .